Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Biosergen Logo
Biosergen Growth Score
73
CB Rank
86822
Heat Score
65
Biosergen develops variants of nystatin with improved properties.
Founded
obfuscation
PublicPost-IPO Equity Trondheim, Sor-Trondelag, Norway1-10 www.biosergen.net
Biotechnology
Pharmaceutical
Overview

Biosergen
Total Funding
obfuscation
Growth Score
73
Heat Score
65

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score73
-10 pts
in past quarter
Heat Score 65
-15 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
See more interactive data and historical milestones on desktop for the best experience

About Biosergen

CB Rank
86822
Biosergen develops variants of nystatin with improved properties.
Founded
obfuscation
PublicPost-IPO Equity Trondheim, Sor-Trondelag, Norway1-10 www.biosergen.net
Biotechnology
Pharmaceutical

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Grant
OBF
in
obfuscation
Funding Round
OBF
in
obfuscation

Key People

Details

Legal Name Biosergen AB
Operating Status Active
Stock Symbol  FRA:8N1
Company Type For Profit
About the Company
Biosergen develops variants of nystatin with improved properties. Its pipeline products include S44HP, an antibiotic that is more potent than nystatin against several fungal pathogens; and nystatin analogues produced through manipulation of the nystatin biosynthetic genes.
Predictions & Insights

Products & Services

BSG005
BSG005 is a genetically improved polyene macrolide antifungal drug designed to kill a broad spectrum of invasive fungal infections, especially in immunocompromised patients.
BSG005 Nano Lung
BSG005 Nano Lung is a formulation of BSG005 designed specifically for targeted treatment of fungal lung infections.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Biosergen Logo
Post-IPO Equity - Biosergen
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Biosergen Logo
Post-IPO Equity - Biosergen
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Biosergen Logo
Post-IPO Equity - Biosergen
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Biosergen Logo
Post-IPO Equity - Biosergen
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Biosergen Logo
Post-IPO Equity - Biosergen
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Biosergen Logo
Post-IPO Equity - Biosergen
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Biosergen Logo
Post-IPO Equity - Biosergen
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Biosergen Logo
Post-IPO Equity - Biosergen
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Biosergen Logo
Post-IPO Equity - Biosergen
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Biosergen Logo
Post-IPO Equity - Biosergen
—
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Rosetta Capital Logo
Rosetta Capital
—
Funding Round - Biosergen Logo
Funding Round - Biosergen
—
Rosetta Capital Logo
Rosetta Capital
—
Funding Round - Biosergen Logo
Funding Round - Biosergen
—
Rosetta Capital Logo
Rosetta Capital
—
Funding Round - Biosergen Logo
Funding Round - Biosergen
—
Rosetta Capital Logo
Rosetta Capital
—
Funding Round - Biosergen Logo
Funding Round - Biosergen
—
Rosetta Capital Logo
Rosetta Capital
—
Funding Round - Biosergen Logo
Funding Round - Biosergen
—
Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 2 Board Members and Advisors 5 Contacts 1

Employee Profiles

Board Members and Advisors

News

News and Press

News•Apr 4, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Feb 10, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Nov 19, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Oct 28, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

IT Spend

$64.2KThis year, Biosergen is projected to spend $64.2K on IT, according to Aberdeen.

Active Website Tech Count

2Biosergen is actively using 2 technologies for its website, according to BuiltWith. These include Common Crawl and  CommonCrawl Top 200m.

Total IP

4The intellectual property of Biosergen includes 4 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Biosergen's headquarters? Biosergen is located in Trondheim, Sor-Trondelag, Norway.Who invested in Biosergen? Biosergen has 2 investors including Rosetta Capital and  SINTEF Venture AS.When was the last funding round for Biosergen? Biosergen closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Biosergen's competitors? Alternatives and possible competitors to Biosergen may include 60 Degrees Pharma, Polichem SA, and  Rompharm Company.How much funding has Biosergen raised to date? Biosergen has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(ccb7a32 1)
|